Correlation of lysosomal enzyme abnormalities in various forms of adult leukaemia

GTN BESLEY, SE MOSS, AD BAIN, AE DEWAR

From the Department of Pathology, Royal Hospital for Sick Children and University of Edinburgh, Edinburgh EH9 1LF, and the *Department of Pathology, University of Edinburgh, Edinburgh EH8 9AG

SUMMARY Lysosomal enzyme activities were studied in cells derived from the following types of leukaemia: chronic myeloid, acute myeloid, acute myelomonocytic, acute monocytic, non-T, non-B cell acute lymphoblastic, T-cell acute lymphoblastic, B-cell chronic lymphocytic and T-cell chronic lymphocytic. Activities of β-hexosaminidase and α-mannosidase were significantly higher in cells from acute monocytic and acute myelomonocytic leukaemias, and somewhat higher in the other myeloid leukaemias, when compared with control granulocytes. Activities of β-hexosaminidase, α-mannosidase, α-fucosidase, β-glucuronidase and acid phosphatase were markedly lower in B cells of chronic lymphocytic leukaemia when compared with control or other leukaemic lymphoid cells. On isoelectric focusing abnormal patterns of β-hexosaminidase, α-mannosidase and β-glucuronidase activities were commonly found in myeloid and non-T, non-B cell leukaemias. All patients with acute myeloid leukaemia exhibited a relative decrease in the B form of β-hexosaminidase activity. The results described show that studies on lysosomal enzymes may assist in the classification of different types of leukaemia.

Recognition of the leukaemic cell type is crucial to the diagnosis, management and prognosis of different types of the disease. In the leukaemias not only cell type but stage of differentiation must be assessed. Classification of the leukaemic cell has generally rested on its morphological, histochemical and immunological characteristics. Recognition of the leukaemic cell type is crucial to the diagnosis, management and prognosis of different types of the disease. In the leukaemias not only cell type but stage of differentiation must be assessed. Classification of the leukaemic cell has generally rested on its morphological, histochemical and immunological characteristics. Such studies may be complemented by the recognition of certain biochemical markers and specific activities of a number of enzymes including terminal deoxynucleotidyl transferase, adenosine deaminase and 5′nucleotidase may be helpful. Studies on lysosomal enzymes have been mainly cytochemical and acid phosphatase and α-naphthyl acetate esterase may provide valuable T cell markers. Quantitative assays of lysosomal enzyme activity may also produce useful data, although only limited reports have appeared so far. Low levels of β-hexosaminidase and β-glucuronidase activity have been reported in B-CLL lymphocytes compared with normal or T-CLL lymphocytes. In other reports where activities of a number of lysosomal hydrolases were studied in cells from patients with different types of leukaemia various changes were noted, in particular high α-mannosidase activities in the non-lymphoid forms of leukaemia.

Previous studies on childhood lymphoblastic leukaemia have demonstrated abnormal patterns of lysosomal enzyme expression in non-T, non-B lymphoblasts after enzyme separation by ion exchange chromatography or isoelectric focusing. Such studies have suggested that such studies will assist in the classification of leukaemias.

Material and methods Fifty-six adults were studied at presentation with various forms of leukaemia. Patients were classified using standard histochemical and immunological techniques which included the following parameters: terminal deoxynucleotidyl transferase, Ia (HLA-Dr) antigen, sheep E "rosettes", non-specific esterase, acid phosphatase, chloroacetate esterase, and reactivity with the following monoclonal antibodies, OKT3, OKT4, OKT6, OKT8, OKM1 (Ortho-Diagnostics Ltd) and MO2, J5 (Coulter Electronics Ltd). From these criteria patients were classified as...
Table 1  Lysosomal enzyme activities in leukaemic and non-leukaemic cells (mean activities ± SD expressed as nmol/min per mg protein; No. of patients or control subjects are indicated in parentheses)

<table>
<thead>
<tr>
<th>Cell type</th>
<th>β-hexosaminidase</th>
<th>α-mannosidase</th>
<th>α-fucosidase</th>
<th>β-glucuronidase</th>
<th>Acid phosphatase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control granulocytes</td>
<td>25.4 ± 5.8 (10)</td>
<td>4.6 ± 1.8 (10)</td>
<td>1.65 ± 0.31 (10)</td>
<td>10.1 ± 2.7 (10)</td>
<td>34.3 ± 8.9 (10)</td>
</tr>
<tr>
<td>CML</td>
<td>43.9 ± 18.7 (7)</td>
<td>14.4 ± 16.1 (5)</td>
<td>1.49 ± 1.12 (6)</td>
<td>7.1 ± 3.9 (5)</td>
<td>27.5 ± 8.4 (5)</td>
</tr>
<tr>
<td>AML</td>
<td>52.4 ± 26.5 (7)</td>
<td>12.9 ± 8.8 (7)</td>
<td>1.14 ± 0.86 (7)</td>
<td>7.3 ± 4.0 (7)</td>
<td>21.7 ± 7.5 (3)</td>
</tr>
<tr>
<td>AMMOL</td>
<td>124 ± 40 (7)</td>
<td>17.1 ± 14.5 (7)</td>
<td>2.39 ± 1.99 (7)</td>
<td>11.1 ± 3.5 (7)</td>
<td>39.1 ± 9.6 (4)</td>
</tr>
<tr>
<td>AMOL</td>
<td>159 ± 41 (7)</td>
<td>16.9 ± 3.3 (7)</td>
<td>5.13 ± 1.25 (7)</td>
<td>17.3 ± 8.3 (7)</td>
<td>42.3 ± 17.4 (7)</td>
</tr>
<tr>
<td>Control lymphocytes</td>
<td>29.6 ± 6.9 (5)</td>
<td>5.5 ± 1.2 (5)</td>
<td>1.46 ± 0.17 (5)</td>
<td>0.8 ± 1.8 (5)</td>
<td>41.5 ± 9.0 (5)</td>
</tr>
<tr>
<td>non-T, non-B ALL</td>
<td>25.4 ± 15.7 (12)</td>
<td>1.66 ± 2.20 (12)</td>
<td>1.10 ± 0.80 (12)</td>
<td>2.94 ± 1.62 (12)</td>
<td>7.8 ± 6.3 (10)</td>
</tr>
<tr>
<td>B-CLL</td>
<td>6.2 ± 5.8 (12)</td>
<td>0.61 ± 0.38 (12)</td>
<td>0.61 ± 0.67 (12)</td>
<td>3.57 ± 1.93 (12)</td>
<td>15.6 ± 10.4 (12)</td>
</tr>
<tr>
<td>T-CLL</td>
<td>23.5 ± 3.9 (3)</td>
<td>1.26 ± 0.58 (3)</td>
<td>1.13 ± 0.32 (3)</td>
<td>4.0 ± 0.5 (3)</td>
<td>15.1 ± 7.0 (3)</td>
</tr>
<tr>
<td>T-ALL</td>
<td>46.3 ± 28.0 (3)</td>
<td>1.21 ± 0.83 (3)</td>
<td>2.30 ± 1.40 (3)</td>
<td>3.47 ± 1.25 (3)</td>
<td>7.1 ± 4.5 (3)</td>
</tr>
</tbody>
</table>

Degrees of significance were evaluated by Student's t test.
* p < 0.001 compared with control granulocytes.
† p < 0.01 compared with control granulocytes.
‡ p < 0.001 compared with control lymphocytes.
§ p < 0.01 compared with control lymphocytes.

follows: chronic myeloid leukaemia (CML) 5 cases; acute myeloid leukaemia (AML) 7 cases; acute myelomonocytic (AMMOL) 7 cases; acute monocytic (AMOL) 7 cases; non-T, non-B cell acute lymphoblastic (non-T, non-B ALL) 12 cases; T-cell acute lymphoblastic leukaemia (T-ALL) 3 cases; B-cell chronic lymphocytic leukaemia (B-CLL) 12 cases; T-cell chronic lymphocytic leukaemia (T-CLL) 3 cases.

Control leucocytes were separated from heparinised peripheral blood, using Ficoll–Paque sedimentation for lymphocytes and dextran (Dextraven 110, Fisons Ltd) sedimentation for granulocytes. Leukaemic cells were collected either by Ficoll–Paque sedimentation or in lymphoblastic leukaemia and CML by sedimentation at 1 g. Cells were washed twice with culture medium (TC 199, Flow Labs Ltd) and stored (up to 18 months) at −70°C as cell pellets prior to analysis. Of the samples studied, 50 of 56 contained in excess of 70% leukaemic cells, 3 had > 60% and 3 had > 50%.

Lysosomal enzyme activities were measured on sonicated cell extracts as reported earlier. Enzyme assays were carried out under optimal conditions using standard fluorogenic substrates in the form of 4-methylumbelliferyl conjugates. Protein concentrations were determined as described earlier.

Isoelectric focusing was carried out in a linear sucrose gradient containing Triton X 100 (1 g/l) and amphotoline (LKB Ltd) in the range pH 3–5–10. Up to six columns of 10 ml working capacity could be run simultaneously and 40 fractions were collected from each column. The pH of each fraction was recorded immediately at 5°C and enzyme activities were measured as indicated above.

Results

Acid hydrolyase activities of leukaemic and non-leukaemic cells are shown in Table 1 and Fig. 1. For all five enzymes, activities were similar (p > 0.01) in fully differentiated lymphocytes and granulocytes. However, significant differences were observed between many leukaemic cells and their mature counterparts. These differences were most clearly seen for β-hexosaminidase and α-mannosidase activities (Fig. 1). Leukaemic cells of myeloid or monocytic origin displayed markedly higher activities of β-hexosaminidase and α-mannosidase; for β-hexosaminidase the order was AMOL > AMMOL > AML > CML > granulocytes. Mean β-hexosaminidase activity of AMOL cells was more than fourfold higher than that (35 nmol/min per mg protein) measured in mature monocytes from a single patient studied with acute monocytes. With regard to lymphoid cells the most striking feature (p < 0.001) was the low activity of all hydrolyases studied in B-CLL lymphocytes. In all acute and chronic lymphoid leukaemias studied, where patients were at presentation, α-mannosidase activity was significantly (p < 0.01) reduced, lowest activity was associated with B-CLL lymphocytes.

On isoelectric focusing of control granulocyte extracts, β-hexosaminidase activity was resolved into two major peaks corresponding to component A (pl 5.2) and component B (pl 7.8) (Fig. 2). The size of the β-hexosaminidase A peak was generally twice that of β-hexosaminidase B, mean ratio of peak heights being 2:0 units (Table 2). In all samples studied from patients with AML, the activity of the B component was markedly reduced (Table 2) giving a
Fig. 1  Activities of \( \beta \)-hexosaminidase and \( \alpha \)-mannosidase in leukaemic and control cells. Activities in control leucocytes are indicated thus:

Granulocytes: Lymph lymphocytes; abbreviations for leukaemic cells are as indicated in Table 1. Patients were at presentation (●) or relapse (○), and of the CML patients studied, one (▲) was in myeloid blast crisis, one (△) in transformation and one (□) in lymphoid blast crisis.

The mean ratio of \( \beta \)-hexosaminidase A peak height to that of \( \beta \)-hexosaminidase B of 7-1 units (range 3-4–19-0 units) (see Table 2). Similar profiles were seen in 3/5 CML patients (mean ratio of all CML samples, 5-7 units), in 3/7 AMMOL patients (mean ratio of all AMMOL samples, 4-1 units) and in 2/7 AMOL patients (mean ratio of all AMOL samples, 2-5 units). Abnormalities in \( \beta \)-hexosaminidase profiles in myeloid/monocytic cells were independent of specific activities. Enzyme profiles in mature monocytes have not yet been satisfactorily established.

For leukaemic lymphoid cells abnormalities of \( \beta \)-hexosaminidase profiles were exhibited in a different fashion. In 4/12 non-T, non-B ALL lymphoblast samples, intermediate peaks of \( \beta \)-hexosaminidase activity (see Fig. 2) were recognised. Similar patterns were also found in one adult T-ALL and one T-CLL patient (Table 3). Abnormal patterns of lymphoblast cells were not seen in the T-CLL patient.

Table 2  Ratio of \( \beta \)-hexosaminidase peak heights in non-lymphoid leukaemias. Activities determined after isoelectric focusing

<table>
<thead>
<tr>
<th>Cell type or source</th>
<th>No of samples</th>
<th>Ratio of A peak: B peak</th>
<th>Frequency of abnormal profiles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal granulocytes</td>
<td>10</td>
<td>2:0</td>
<td>1:6–2:7</td>
</tr>
<tr>
<td>CML*</td>
<td>5</td>
<td>5:7</td>
<td>1:1–10:4</td>
</tr>
<tr>
<td>AML</td>
<td>7</td>
<td>7:1</td>
<td>3:4–19:0</td>
</tr>
<tr>
<td>AMMOL</td>
<td>7</td>
<td>4:1</td>
<td>1:1–13:0</td>
</tr>
<tr>
<td>AMOL</td>
<td>7</td>
<td>2:5</td>
<td>1:0–8:0</td>
</tr>
</tbody>
</table>

*Leukaemic cells derived from patients with the following leukaemias: chronic myeloid (CML), acute myeloid (AML), acute myelomonocytic (AMMOL), and acute monocytic (AMOL).

Fig. 2  Isoelectric focusing profiles of lysosomal enzyme activities in leukaemic and control cells. Activities of \( \beta \)-hexosaminidase (left), \( \alpha \)-mannosidase (centre) and \( \beta \)-glucuronidase (right) are plotted against fraction pH at 5°C. Cell extracts were derived from control granulocytes (●), a patient with acute myeloid leukaemia (○), control lymphocytes (▲), and a patient with non-T, non-B cell acute lymphoblastic leukaemia (△).
Correlation of lysosomal enzyme abnormalities in various forms of adult leukaemia

Table 3  Frequency of abnormal profiles of lysosomal enzyme activity in leukaemic cells. Activities were determined in fractions following isoelectric focusing

<table>
<thead>
<tr>
<th>Leukaemic cell source*</th>
<th>Enzyme activity profile</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β-hexosaminidase</td>
</tr>
<tr>
<td>CML 3/5</td>
<td>0/5</td>
</tr>
<tr>
<td>AML 7/7</td>
<td>6/7</td>
</tr>
<tr>
<td>AMMOL 3/7</td>
<td>3/7</td>
</tr>
<tr>
<td>AMOL 2/7</td>
<td>3/7</td>
</tr>
<tr>
<td>non-T, non-B ALL</td>
<td>4/12</td>
</tr>
<tr>
<td>T-ALL 1/3</td>
<td>1/3</td>
</tr>
<tr>
<td>T-CLL 1/3</td>
<td>0/3</td>
</tr>
<tr>
<td>B-CLL 0/12</td>
<td>0/12</td>
</tr>
</tbody>
</table>

*Cells were derived from patients with the following types of leukaemia: chronic myeloid (CML), acute myeloid (AML), acute myelomonocytic (AMMOL), acute monocytic (AMOL), non-T, non-B cell acute lymphoblastic (non-T, non-B ALL), T-cell acute lymphoblastic (T-ALL), T-cell chronic lymphocytic (T-CLL), B-cell chronic lymphocytic (B-CLL).

α-mannosidase and β-glucuronidase activity were commonly found in cells from patients with acute forms of both myeloid/monocytic and lymphoid leukaemia, as indicated in Table 3. The type of abnormality was similar in all cases (both myeloid and lymphoid types) and resulted in an apparent shift of enzyme activity to a more anodic position. For α-mannosidase the major peak shifted from pI 6.2 to pI 5.1 and for β-glucuronidase the major peak shifted from pI 7.9 to pI 7.0 (Fig. 2). The most consistent changes were seen for AML patients where abnormal α-mannosidase profiles were seen in 6/7 patients, and abnormal β-glucuronidase profiles were found in 7/7 patients. Activity profiles for α-fucosidase were also studied in all cases: a normal profile was observed in all but one case (T-ALL patient) where the major enzyme shifted from pI 6.2 to pI 5.2, similar to the change observed for α-mannosidase.

The abnormal expression of lysosomal enzyme profiles in these leukaemic patients did not appear to correlate with other markers studied nor with the clinical expression of the disease.

Discussion

Previous studies from this laboratory and elsewhere have concentrated on patterns of lysosomal enzyme expression in acute forms of childhood lymphoblastic leukaemia. In the current report, studies have been extended to cover other forms of leukaemia in adults. Although cytochemical analyses of lysosomal enzyme activities are fairly widely used, quantitative assays which may complement these, have been less extensively studied. Studies on different populations of normal peripheral leucocytes have suggested that specific cells possess characteristic levels of hydrolase activity. Many lysosomal enzyme activities, including β-hexosaminidase, β-glucuronidase and acid phosphatase, but excluding α-mannosidase, were found to be high in normal monocytes. In leukaemic monocytoid cells activities were somewhat higher in one report but in our study activities, particularly of β-hexosaminidase and α-mannosidase, were markedly raised. High α-mannosidase activity in these cells may thus reflect a change associated with malignancy rather than a monocytic characteristic. A similar biochemical change associated with malignancy may occur in B-CLL lymphocytes. Compared with T lymphocytes, normal B lymphocytes have been reported to possess slightly lower activities of β-hexosaminidase, β-glucuronidase and acid phosphatase but rather higher α-mannosidase activities. Yet α-mannosidase activity was markedly higher (p < 0.001) in B-CLL lymphocytes in our study, and others. Low activities of β-hexosaminidase and β-glucuronidase in B-CLL lymphocytes confirm previous biochemical and cytochemical analysis, although our findings would suggest a general depression of lysosomal activity in these cells, as suggested by EM studies. Activities in T-CLL lymphocytes were not depressed to the same extent in the three patients studied here and one elsewhere. In all lymphoid leukaemias, apart from β-hexosaminidase, the activities of lysosomal enzymes were somewhat lower than those of control cells (Table 1); a similar finding has been reported by others.

To characterise further the nature of lysosomal enzyme activity in leukaemic cells, enzyme components were separated by isoelectric focusing. It has been established that intermediate forms of β-hexosaminidase activity are expressed in lymphoblasts of most (approx. 80%) cases of childhood non-T, non-B ALL. In the current study intermediate components were identified in only one third of adults with non-T, non-B ALL (Table 3). No adults with B-CLL expressed abnormal enzyme patterns despite having significantly lowered enzyme activities. One patient with T-CLL had an abnormal β-hexosaminidase profile which was similar to the non-T, non-B ALL pattern. However in one T-ALL adult, all four hydrolase profiles were clearly abnormal; intermediate forms of β-hexosaminidase and anodic forms of α-mannosidase (pI 4.9), α-fucosidase (pI 5.2) and β-glucuronidase (pI 7.0) activities were present. This patient who was in relapse was classified as having T-ALL based on focal acid phosphatase activity, positive reactions with OKT3 and OKT6 and the presence of TdT at a level of 91 units/10⁶ cells.

Anodic forms of α-mannosidase were commonly
found (Table 3) in acute leukaemias of both lymphoid or myeloid origin but not in the chronic leukaemias studied. These enzymes may therefore reflect a biochemical event associated with acute forms of malignancy in these cells rather than that of a specific cell marker. Previous studies\(^1,3\) failed to recognise abnormal α-mannosidase profiles in three children with AML, although abnormal α-mannosidase profiles were seen in those non-T, non-B ALL patients whose cells expressed intermediate β-hexosaminidase activity. In this study abnormal α-mannosidase profiles in lymphoid leukaemias appeared identical to those in myeloid or monocytic forms of leukaemia.

Although intermediate forms of β-hexosaminidase were seen in some lymphoid leukaemias, these components were never found in the non-lymphoid leukaemias. But within this latter group, specific patterns of β-hexosaminidase expression were identified as a low B component compared with the A component (see Table 2). The nature of this abnormality is not known particularly since abnormal profiles did not correlate with specific activities. Precisely why lysosomal enzyme activities or patterns of expression are altered in leukaemia is not defined by these or other studies. However, lysosomal enzymes are glycoprotein in nature and a number of changes involving the oligosaccharide structure of glycoproteins\(^2,12\) and glycolipids\(^23,24\) have been associated with forms of malignancy and cellular differentiation. Lysosomal enzymes may undergo similar changes: for example, abnormal sialylation may result in altered isoelectric points of enzymes. Studies of lysosomal enzymes may therefore provide a useful means of studying oligosaccharide abnormalities associated with malignancy whilst at the same time provide useful enzyme markers in leukaemia.

We thank consultant haematologists at the following hospitals for samples from their patients: Royal Infirmary, Edinburgh; Western General, Edinburgh; Bangour General; Falkirk Royal Infirmary and Fife Area laboratories, Kirkcaldy. We thank Professor Sir Alastair Currie for his support and interest and the Haematology Department, Royal Infirmary, Edinburgh for Tdt estimations. We are grateful to the Cancer Research Campaign for financial support and one of us (AED) was supported by a grant to the Edinburgh Lymphoma Group.

References


Requests for reprints to: Dr GTN Besley, Department of Pathology, Royal Hospital for Sick Children, Edinburgh EH9 1LF, Scotland.
Correlation of lysosomal enzyme abnormalities in various forms of adult leukaemia.
G T Besley, S E Moss, A D Bain and A E Dewar

doi: 10.1136/jcp.36.9.1000

Updated information and services can be found at:
http://jcp.bmj.com/content/36/9/1000

**Email alerting service**

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/